<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375020</url>
  </required_header>
  <id_info>
    <org_study_id>icel</org_study_id>
    <nct_id>NCT04375020</nct_id>
  </id_info>
  <brief_title>GABA and Beta-cell Regeneration</brief_title>
  <official_title>GABA From Medical Nutrition to Pancreatic Beta-cell Regeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health and Population, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health and Population, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GABA(gamma-Aminobutyric acid) may be used for decreasing anti-gad antibodies and leads
      beta-cell regeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients with type I diabetes were in 2 groups, had been monitored in a private clinic,
      number 50 each group, with 30 females and 20 males after the written consent of all patients.

      All the patients Lied between 18-25 years old with 5-10 years of diabetes onset.

      The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times
      daily and they received GABA nutritional supplement 750mg per day.

      The second group was only on insulin injection in the form of toujeo once daily and Novorapid
      3 times daily.

      In the first group;the investigator measured fasting c peptide levels before and after 6
      months of GABA 750mg daily.Also,the investigator measured anti gad antibodies before and
      after 6 months of treatment.

      In the second group,the investigator measured c peptide levels and anti-gad antibodies at the
      beginning of the trial and after 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">May 2, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>gaba decrease anti gad antibodies</measure>
    <time_frame>6 months</time_frame>
    <description>gaba 750 mg daily for type 1 diabetes patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gaba improve c peptide levels</measure>
    <time_frame>6 months</time_frame>
    <description>gaba 750 mg pe day for type 1 diabetes patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>group1 on GABA</arm_group_label>
    <description>The first group was on insulin therapy in the form of toujeo once daily and Novorapid 3 times daily and they received GABA nutritional supplement 750mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 on just insulin</arm_group_label>
    <description>The second group was only on insulin injection in the form of toujeo once daily and Novorapid 3 times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GABA</intervention_name>
    <description>GABA nutritional supplement 750mg per day for 6 months</description>
    <arm_group_label>group1 on GABA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        observation prospective study 100 patients with type I diabetes were int 2 groups, had been
        monitored in a private clinic, number 50 each group, with 30 females and 20 males after the
        written consent of all patients.

        All the patients Lied between 18-25 years old with 5-10 years of diabetes onset.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - type 1 diabetes patients age from 18 to 25 years on basal bolus insulin

        Exclusion Criteria:

        thyroid problems liver disease kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Mahmoud Younis</name>
      <address>
        <city>Cairo</city>
        <zip>11865</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 2, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health and Population, Egypt</investigator_affiliation>
    <investigator_full_name>mahmoud younis</investigator_full_name>
    <investigator_title>consultant</investigator_title>
  </responsible_party>
  <keyword>type 1diabetes, gaba</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

